XENE insider ownership: who sold, why, and what they still hold

What stands out

Two officers bought shares: Ian Mortimer (30K shares, $1.1M) and Thomas Kelly (15K shares, $560K). These are the first by current officers or directors since Jan 21, 2022.Ian Mortimer: purchase, Sep 30, 2026 · Thomas Kelly: purchase, Sep 30, 2026

A share of stake is shown for 0 of the 6 officers and directors who sold. 12 are left out

Left out: Ian Mortimer, Gary Patou, Dawn Svoronos, Steven Gannon, Patrick Machado, Elizabeth Garofalo, Christopher Kenney, Andrea DiFabio, Gillian Cannon, Justin Gover, Darren Cline and Thomas Kelly (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Ian Mortimer

President & CEO, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$20.3MDisclosed plan

Christopher Kenney

Chief Medical Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$670KDisclosed plan

Steven Gannon

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$641KNo plan disclosed

Andrea DiFabio

Chief Legal Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$231KDisclosed plan

Gary Patou

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$70KDisclosed plan

All 6 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

Sep 30, 20262 executives bought 45K shares ($1.7M).

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Ian Mortimer President & CEO, Director	30,000	$37.38	n/a	n/a	Sep 30, 2026	Oct 1, 2026
Thomas Kelly Chief Financial Officer	15,000	$37.32	n/a	n/a	Sep 30, 2026	Oct 1, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Common questions

Is the Xenon Pharmaceuticals Inc. CEO selling stock?

Yes. Ian Mortimer sold 354K shares ($20.3M) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Xenon Pharmaceuticals Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 97% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 3% had no disclosed plan. A trading plan schedules sales in advance.

Are any Xenon Pharmaceuticals Inc. insiders buying?

Yes. 2 officers or directors reported 2 purchases in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold6 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Ian Mortimer President & CEO, Director	$20.3M 354K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Christopher Kenney Chief Medical Officer	$670K 11K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Steven Gannon Director	$641K 10K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Andrea DiFabio Chief Legal Officer	$231K 3.9K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Gary Patou Director	$70K 1.3K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Gillian Cannon Director	$63K 1.2K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

The full ownership picture0 of 12 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 16, 2025

Sold

Held Oct 16, 2026

Still held

Ian Mortimer

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Ian Mortimer are complete.

President & CEO, Director

n/a

−354K

n/a

Vesting, gifts, unvested awards and holding lines for Ian Mortimer

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ian Mortimer are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
250,000	$44.37	Mar 10, 2034	$0
275,000	$35.48	Mar 11, 2035	$505K
350,000	$42.15	Jan 8, 2036	$0

Estimate: options held × ($37.32 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Gary Patou

Director

n/a

−1.3K

n/a

Vesting, gifts, unvested awards and holding lines for Gary Patou

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Gary Patou are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,542	$38.16	Jun 4, 2034	$0
17,012	$30.73	Jun 4, 2035	$112K
10,507	$53.46	Jun 2, 2036	$0

Estimate: options held × ($37.32 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Dawn Svoronos

Director

n/a

Vesting, gifts, unvested awards and holding lines for Dawn Svoronos

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Dawn Svoronos are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−1.4Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,542	$38.16	Jun 4, 2034	$0
17,012	$30.73	Jun 4, 2035	$112K
10,507	$53.46	Jun 2, 2036	$0

Estimate: options held × ($37.32 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Steven Gannon

Director

n/a

−10K

n/a

Vesting, gifts, unvested awards and holding lines for Steven Gannon

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Steven Gannon are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−1.4Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,542	$38.16	Jun 4, 2034	$0
17,012	$30.73	Jun 4, 2035	$112K
10,507	$53.46	Jun 2, 2036	$0

Estimate: options held × ($37.32 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Patrick Machado

Director

n/a

Vesting, gifts, unvested awards and holding lines for Patrick Machado

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Patrick Machado are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,542	$38.16	Jun 4, 2034	$0
17,012	$30.73	Jun 4, 2035	$112K
10,507	$53.46	Jun 2, 2036	$0

Estimate: options held × ($37.32 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Elizabeth Garofalo

Director

n/a

Vesting, gifts, unvested awards and holding lines for Elizabeth Garofalo

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Elizabeth Garofalo are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
16,500	$18.56	Jun 2, 2031	$309K
15,542	$38.16	Jun 4, 2034	$0
17,012	$30.73	Jun 4, 2035	$112K
10,507	$53.46	Jun 2, 2036	$0

Estimate: options held × ($37.32 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Christopher Kenney

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Christopher Kenney are complete.

Chief Medical Officer

n/a

−11K

n/a

Vesting, gifts, unvested awards and holding lines for Christopher Kenney

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christopher Kenney are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
100,000	$44.37	Mar 10, 2034	$0
80,000	$35.48	Mar 11, 2035	$147K
100,000	$42.15	Jan 8, 2036	$0

Estimate: options held × ($37.32 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Andrea DiFabio

Chief Legal Officer

n/a

−3.9K

n/a

Vesting, gifts, unvested awards and holding lines for Andrea DiFabio

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Andrea DiFabio are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
100,000	$44.37	Mar 10, 2034	$0
80,000	$35.48	Mar 11, 2035	$147K
80,000	$42.15	Jan 8, 2036	$0

Estimate: options held × ($37.32 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Gillian Cannon

Director

n/a

−1.2K

n/a

Vesting, gifts, unvested awards and holding lines for Gillian Cannon

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Gillian Cannon are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,542	$38.16	Jun 4, 2034	$0
17,012	$30.73	Jun 4, 2035	$112K
10,507	$53.46	Jun 2, 2036	$0

Estimate: options held × ($37.32 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Justin Gover

Director

n/a

Vesting, gifts, unvested awards and holding lines for Justin Gover

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Justin Gover are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,542	$38.16	Jun 4, 2034	$0
17,012	$30.73	Jun 4, 2035	$112K
10,507	$53.46	Jun 2, 2036	$0

Estimate: options held × ($37.32 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Darren Cline

Chief Commercial Officer

n/a

Vesting, gifts, unvested awards and holding lines for Darren Cline

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Darren Cline are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
185,800	$31.49	Jun 22, 2035	$1.1M
40,000	$42.15	Jan 8, 2036	$0

Estimate: options held × ($37.32 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Thomas Kelly

Chief Financial Officer

n/a

Vesting, gifts, unvested awards and holding lines for Thomas Kelly

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Thomas Kelly are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
225,000	$41.90	Oct 14, 2035	$0

Estimate: options held × ($37.32 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Holdings and share of stake for Xenon Pharmaceuticals Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$22.0M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $22.0M across 381,589 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $21.3M · 97%

The lighter segment is sales with no plan disclosed in the filing ($641K), including tax-related sales outside a plan.

No plan disclosed · $641K

Sales with no 10b5-1 plan and no tax reference in the filing. $641K of it is Steven Gannon. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Steven Gannon, Aug 11, 2026

Taxes

$1.7M of sales (7.9%) cite tax obligations in their footnotes, $1.7M of them also under a plan. Separately, 2,832 shares ($151K) were withheld by the company for taxes, which isn't a market sale. Example: Christopher Kenney, Aug 28, 2026

Purchases · 2 buyers (2 trades)

2 officers and directors bought shares in this period, in 2 trades(Form 4 code P, leaving out rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust). Across all their filings on record there are 13 purchase trades.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Ian Mortimer President & CEO, Director	354K	$20.3M	100%	92%	Nov 28, 2025 to Mar 13, 2026
Christopher Kenney Chief Medical Officer	11K	$670K	100%	3%	Mar 10, 2026 to Aug 28, 2026
Steven Gannon Director	10K	$641K	0%	3%	Aug 11, 2026 to Aug 11, 2026
Andrea DiFabio Chief Legal Officer	3.9K	$231K	100%	1%	Mar 10, 2026 to Mar 13, 2026
Gary Patou Director	1.3K	$70K	100%	0.3%	Jun 5, 2026 to Jun 5, 2026
Gillian Cannon Director	1.2K	$63K	100%	0.3%	Jun 5, 2026 to Jun 5, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$4K	$4K	$0	$0
Dec 2025	$1.1M	$1.1M	$0	$0
Jan 2026	$1.8M	$1.8M	$0	$0
Feb 2026	$0	$0	$0	$0
Mar 2026	$17.8M	$17.8M	$0	$0
Apr 2026	$0	$0	$0	$0
May 2026	$0	$0	$0	$0
Jun 2026	$133K	$133K	$0	$0
Jul 2026	$0	$0	$0	$0
Aug 2026	$1.1M	$426K	$0	$641K
Sep 2026	$0	$0	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

More than usual: about 2.3x the 5-year average. 6 insiders sold; the average is 4 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 16, 2026 Latest 12 months	382K	6	$22.0M
Oct 16, 2025 1 year earlier	104K	4	$4.2M
Oct 16, 2024 2 years earlier	49K	4	$2.1M
Oct 17, 2023 3 years earlier	212K	5	$8.3M
Oct 17, 2022 4 years earlier	461K	4	$16.6M
Oct 17, 2021 5 years earlier	17K	2	$321K

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty12 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Xenon Pharmaceuticals Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology369 filings on record, 30 filed in the 12-month period, and how we read them

All 369 Forms 3, 4 and 5 on record for Xenon Pharmaceuticals Inc. (SEC CIK 1582313), filed from Nov 4, 2014 to Oct 1, 2026; 30 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (21)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Sherry Aulin	Dec 19, 2024	No balance on record
Sherrington Robin	Mar 12, 2024	8,398 shares, last reported balance as of Mar 7, 2024
James Empfield	Mar 12, 2024	10,000 shares, last reported balance as of Aug 12, 2022
Christopher Von Seggern	Mar 12, 2024	4,000 shares, last reported balance as of Dec 6, 2021
Mohammad Azab	Dec 20, 2023	74,225 shares, last reported balance as of Dec 19, 2023
Simon Pimstone	Jun 2, 2023	6,000 shares, last reported balance as of Jun 1, 2023
Michael Hayden	Jun 3, 2021	322,685 shares, last reported balance as of May 18, 2021
Frank Holler	Jun 1, 2021	144,837 shares, last reported balance as of May 27, 2021
Michael Tarnow	May 20, 2021	77,942 shares, last reported balance as of May 18, 2021
Clarissa Desjardins	Jun 2, 2020	No balance on record
Ernesto Aycardi-Fonseca	Mar 13, 2020	No balance on record
Richard Scheller	Sep 18, 2019	7,000 shares, last reported balance as of Aug 10, 2017
Charles Cohen	Dec 13, 2018	6,550 shares, last reported balance as of Dec 11, 2018
BVF PARTNERS L P/IL	Mar 29, 2018	356,928 shares, last reported balance as of Mar 27, 2018
Paul Goldberg	Oct 24, 2017	6,000 shares, last reported balance as of Sep 24, 2015
Raymond Winquist	Aug 21, 2017	1,000 shares, last reported balance as of Aug 18, 2017
Johnston Evans	May 6, 2015	444,655 shares, last reported balance as of Nov 9, 2014
Evan Stein	May 4, 2015	914,758 shares, last reported balance as of Apr 30, 2015
Karen Corraini	Mar 19, 2015	2,057 shares, last reported balance as of Nov 4, 2014
MX Associates, LLP	Jan 7, 2015	No balance on record
Gary Bridger	Nov 25, 2014	No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Xenon Pharmaceuticals Inc. insiders sold $22.0M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the Xenon Pharmaceuticals Inc. CEO selling stock?

Why are Xenon Pharmaceuticals Inc. insiders selling?

Are any Xenon Pharmaceuticals Inc. insiders buying?

The evidence

No plan disclosed · $641K

Taxes

Purchases · 2 buyers (2 trades)

Sales by month